Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810651 · ClinicalTrials.gov registry record · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
A Early Phase 1 study of Wilms Tumor and Renal Tumor, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03810651 is a Early Phase 1 study of Wilms Tumor and Renal Tumor that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 28 participants, below the 291-participant average among 14 other Wilms Tumor trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03810651, a Early Phase 1 study of Wilms Tumor and Renal Tumor, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.
Conditions Studied
Interventions
- OTHER Proton beam radiation using pencil beam scanning
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-12-26 |
| Est. Completion | 2027-10-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03810651
The ClinicalTrials.gov registry entry for NCT03810651 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 291-participant average among 14 other Wilms Tumor trials with a reported enrollment target (90% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Wilms Tumor appearing as the primary indexed condition, and to 1 intervention - of which Proton beam radiation using pencil beam scanning is the first listed.
NCT03810651 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03810651 about?
NCT03810651 is a clinical study titled "Pencil Beam Scanning in Patients With Renal Tumors". This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.
What is the current status of trial NCT03810651?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2017-12-26. Estimated completion is 2027-10-30.
What conditions does trial NCT03810651 study?
This clinical trial studies the following conditions: Wilms Tumor, Renal Tumor.
What interventions are being tested in trial NCT03810651?
The interventions under investigation include: Proton beam radiation using pencil beam scanning (OTHER).
Who is sponsoring clinical trial NCT03810651?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03810651 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wilms Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
International PPB/DICER1 Registry
RECRUITING
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RECRUITING · Phase 1
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.